C4 Therapeutics Inc. (CCCC) has shared promising data from its Phase 1 clinical trial evaluating cemsidomide, an orally bioavailable IKZF1/3 degrader, in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM).
With enrollment now complete, the trial continues to demonstrate cemsidomide's differentiated safety and tolerability profile, along with potentially class-leading anti-myeloma activity.
The findings support clear development paths for second-line and later-stage patient populations. Notably, the combination therapy achieved a 50% overall response rate (ORR) at the highest dose level (100 g) and a 40% ORR at the 75 g dose level in a heavily pre-treated RRMM population. Responses were observed across dose levels, with a median duration of response of 9.3 months as of the data cut-off date, although the median duration has not yet been reached at the two highest doses. Importantly, there were no discontinuations attributed to cemsidomide and only a few dose reductions, underscoring a safety profile that may be well-suited for combination regimens.
Based on these results, C4T plans to pursue a differentiated development strategy with two distinct opportunities for accelerated approval in second-line and later treatment settings.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.